Ichor Medical Systems said it will develop electroporation devices for use in Pfizer's ($PFE) preclinical cancer vaccine research efforts. Neither side is disclosing financial details, but San Diego-based Ichor gets an upfront payment plus milestone and royalty cash based on potential future sales. Both sides will share some development expenses. Ichor is known for its TriGrid Delivery System, an integrated and fully automated device for electroporation-mediated DNA administration in humans. The technology enables the delivery of DNA drugs and vaccines for diseases such as cancer, malaria, hepatitis B and HIV, Ichor said. Release